Cargando…

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

We report physiologically based pharmacokinetic‐modeling analyses to determine olaparib (tablet or capsule) drug–drug interactions (DDIs). Verified DDI simulations provided dose recommendations for olaparib coadministration with clinically relevant CYP3A4 modulators to eliminate potential risk to pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pilla Reddy, Venkatesh, Bui, Khanh, Scarfe, Graeme, Zhou, Diansong, Learoyd, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585620/ https://www.ncbi.nlm.nih.gov/pubmed/29717476 http://dx.doi.org/10.1002/cpt.1103

Ejemplares similares

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors
por: Pilla Reddy , Venkatesh, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
por: Taskar, Kunal S., et al.
Publicado: (2019)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy
por: George, Blessy, et al.
Publicado: (2020)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
por: Gill, Jaidip, et al.
Publicado: (2022)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
por: Pan, Xian, et al.
Publicado: (2021)

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
por: Poveda, Andres, et al.
Publicado: (2021)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
por: Lim, Andrew, et al.
Publicado: (2023)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
por: Le Merdy, Maxime, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
por: Wang, Ziteng, et al.
Publicado: (2022)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
por: Patiño-Rodríguez, Omar, et al.
Publicado: (2014)

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
por: Das, Shampa, et al.
Publicado: (2015)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients
por: Pei, Ling, et al.
Publicado: (2023)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
por: Hanna, Catherine, et al.
Publicado: (2020)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy
por: Oi Yan Chan, Joyce, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment
por: Gao, Dongmei, et al.
Publicado: (2023)

Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs
por: Yang, Bin, et al.
Publicado: (2017)

Correction to: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium
por: van Groen, Bianca D., et al.
Publicado: (2020)

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
por: Jo, Heeseung, et al.
Publicado: (2021)

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model
por: Chen, Yuan, et al.
Publicado: (2019)

Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses
por: Zozaya, Heidi, et al.
Publicado: (2013)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria
por: Sae‐heng, Teerachat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gk2gkqek53liivkj313o7hhajj